10-Q · May 13, 2026
Vivani Medical's Q4 2026 results reflect ongoing challenges, with reported revenue of $0.0 and an EPS of -$0.09, consistent with prior periods, indicating continued operational losses. R&D expenses slightly increased to…
Earnings analysis · 10-Q
VANI earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The filing depicts Vivani as an early-stage clinical company with no approved products, continuing losses, and a substantial need for additional capital. The six-month net loss improved modestly to $13.2 million from…
Read full summary
The filing depicts Vivani as an early-stage clinical company with no approved products, continuing losses, and a substantial need for additional capital. The six-month net loss improved modestly to $13.2 million from $13.4 million year over year, and the company plans mid-2026 Phase 1 trials for NPM-139 and NPM-133. However, regulatory uncertainty around the 505(b)(2) pathway, potential clinical-study requirements, litigation exposure, and emerging tariff risks remain significant headwinds.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Six-Month Loss Improved Slightly
Six-month net loss was $13.2 million, compared with $13.4 million in the six months ended June 30, 2025, an improvement of $0.2 million, or approximately 1.5%.
-
Clinical Pipeline Advancing
Management plans to initiate Phase 1 clinical trials for NPM-139 and NPM-133 in mid-2026, while NPM-115 has completed a Phase 1 study.
-
Regulatory Experience Remains Early
The company has been granted 1 U.S. IND and 1 Australian HREC request, although it has submitted 0 NDAs to the FDA or comparable foreign agencies.
-
Disclosure Controls Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes in internal control over financial reporting during or after the quarter.
What to watch
-
Substantial Funding Requirement
The company reported a six-month net loss of $13.2 million and an accumulated deficit of $161.7 million as of June 30, 2026. Management states that substantial additional financing will be required and that failure to obtain capital could delay, reduce, or terminate development activities.
-
505(b)(2) Pathway Uncertainty
If the FDA does not accept the Section 505(b)(2) pathway for NPM-139 or NPM-133, additional clinical studies, including a cardiovascular outcomes study, may be required. The filing states this could create significant additional costs and delays.
-
Tariff and Supply-Chain Exposure
The filing identifies new trade-policy exposure, including a U.S. baseline tariff of 10% and a potential 15% tariff on most imports from the European Union. Tariffs on APIs, raw materials, and device components could increase costs and disrupt research, development, and production timelines.
-
Material Litigation Exposure
The company faces a pending Oppenheimer breach-of-contract claim seeking no less than $1.625 million, while Pixium claims approximately €5.1 million, or about $5.6 million, in damages in separate litigation.
Management's outlook
No quantitative revenue or EPS guidance is provided in the extracted 10-Q text. The filing states that the company does not anticipate product-sale revenue for the foreseeable future and may never become profitable.
Earlier filings 4
10-K · March 26, 2026
Vivani Medical is a clinical‑stage biopharma developing NanoPortal™ subdermal implants (lead program NPM-139 semaglutide) and recently reported positive first‑in‑human LIBERATE-1 data and preclinical semaglutide…
10-Q · November 13, 2025
Vivani reported a Q3 net loss per share of $(0.11), unchanged from the prior-year quarter, while total operating expenses rose to $6,725k from $6,309k (up $416k). Cash and cash equivalents declined sharply to $2,628k at…
10-Q · May 13, 2025
Vivani reported a Q1 2025 net loss of $6,302,000 (EPS -$0.11) versus a net loss of $6,039,000 (EPS -$0.12) in Q1 2024. The Company achieved clinical milestones (first GLP‑1 implant administered and full enrollment in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.